Evidence map›Paper›PMID 36139983›Full record

ArticleAntibiotics (Basel, Switzerland)2022

Eric H Young, Kelsey A Strey, Grace C Lee, Travis J Carlson, Jim M Koeller, Kelly R Reveles

Open access · goldAbstract read
In one paragraph

Article in Antibiotics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
  3. Variety ofGerms · 2026
    Article
  4. Observational
  5. Article
  6. Article
  7. Article
  8. Examining the impact of racial disparities onInfection control and hospital epidemiology · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Eric H YoungCollege of Pharmacy, The University of Texas at Austin, Austin, TX 78701, USA.
Kelsey A StreyCollege of Pharmacy, The University of Texas at Austin, Austin, TX 78701, USA.
Grace C LeeCollege of Pharmacy, The University of Texas at Austin, Austin, TX 78701, USA.
Travis J CarlsonFred Wilson School of Pharmacy, High Point University, High Point, NC 27268, USA.ORCID 0000-0001-9564-3030
Jim M KoellerCollege of Pharmacy, The University of Texas at Austin, Austin, TX 78701, USA.
Kelly R RevelesCollege of Pharmacy, The University of Texas at Austin, Austin, TX 78701, USA.
The University of Texas Health Science Center at San Antonio · USHigh Point University · US

Funding

The University of Texas at Austin None
6 · The paper itself

Abstract

Clostridioides difficile infection (CDI) disproportionately affects certain populations, but few studies have investigated health outcome disparities among patients with CDI. This study aimed to characterize CDI treatment and health outcomes among patients by age group, sex, race, and ethnicity. This was a nationally representative, retrospective cohort study of patients with laboratory-confirmed CDI within the Premier Healthcare Database from January 2018 to March 2021. CDI therapies received and health outcomes were compared between patients by age group, sex, race, and Hispanic ethnicity using bivariable and multivariable statistical analyses. A total of 45,331 CDI encounters were included for analysis: 38,764 index encounters and 6567 recurrent encounters. CDI treatment patterns, especially oral vancomycin use, varied predominantly by age group. Older adult (65+ years), male, Black, and Hispanic patients incurred the highest treatment-related costs and were at greatest risk for severe CDI. Male sex was an independent predictor of in-hospital mortality (aOR 1.17, 95% CI 1.05−1.31). Male sex (aOR 1.25, 95% CI 1.18−1.32) and Black race (aOR 1.29, 95% CI 1.19−1.41) were independent predictors of hospital length of stay >7 days in index encounters. In this nationally representative study, CDI treatment and outcome disparities were noted by age group, sex, and race.

Indexed as

Clostridioides difficiledisparitiesepidemiologymortality

Identifiers

PMID36139983
PMCPMC9495221
OpenAlexW4295063305

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.